CATALYSTYahoo • 4d ago
National Research: Q3 Earnings Snapshot(NRC) on Tuesday reported earnings of $4.The Lincoln, Nebraska-based company said it had profit of 21 cents per share.
Why NRC Stock advanced +0.09% Today — RQD Quant Desk Flash
$23.49 +0.09% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $23.45
NRC Health (NRC) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C • HOLD / WATCH
Cap $519.6M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $23.45 (-0.17%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 11.5% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY • 55.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE+3.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NRC)Realized 20D OHLCV Swing Band: ±9%
Deterministic 5-Pillar Attribution (65/100 Composite)
🔍 WHY NRC SCORES 65/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (28% of score)
SEC XBRL FY 2025 (10-K): 11.5% FCF Margin ($15.7M FCF) & 52% Gross Margin
▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (18% of score)
20D Institutional Volume Accumulation (±9% realized swing band)
▼ #1 Drag / Risk Factor: Macro Regime Fit11/20 pts (-9 pt drag)
Macro rate sensitivity & RSI-14 (66.7) create a -9 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$20.33-0.9% Next Q
57
Q2 (-2Q)Grade C$20.15+8.8% Next Q
60
Q3 (-1Q)Grade C+$21.93+7.1% Next Q
62
CurrentGrade C$23.49+1.3% Hist 90D α
65
Trajectory: C (57) → C (65)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the NRC Bull Thesis Could Fail
Even with a 65/100 (C) score, NRC faces multiple-compression risk if 44.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Priced at 45x earnings—high expectations leave less room for a lukewarm quarter.
⚠️ Forensic Kill-Switch #2
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($21.22) or 200D SMA ($19.17) invalidates the momentum regime and cuts Target Base ($24.23) toward Bear Floor ($18.90).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NRC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NRC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NRC Stock advanced +0.09% Today — RQD Quant Desk Flash
NRC Health (NRC) advanced +0.09% to $23.49, trading at 93% of its 52-week range ($11.74 – $24.4). Solid steady margins (21% return on capital), mixed timing at 45x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 93% of its 52-week range ($11.74 – $24.4) with RSI-14 at 66.7 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9% around $23.49 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 52% gross margin and $15.7M annual free cash flow.
Live NRC Headlines & Catalysts
CATALYSTBenzinga • 4d ago
Citizens Maintains Market Outperform on NRC Health, Raises Price Target to $27Citizens analyst Constantine Davides maintains NRC Health (NASDAQ:NRC) with a Market Outperform and raises the price target from $26 to $27.
MARKET WIREYahoo • 4d ago
National Research Corporation Q3 2026 Earnings Call SummaryMoby summary of National Research Corporation's Q3 2026 earnings call
CATALYSTYahoo • 4d ago
NRC Health (NRC) Q3 2026 Earnings Call TranscriptLandmark contract implementation drove 11% revenue growth and margin expansion.
CATALYSTYahoo • 4d ago
National Research Q3 Earnings Call HighlightsNational Research (NASDAQ:NRC), which operates as NRC Health, reported third-quarter revenue growth of 11% to $38 million as a large customer implementation went live on schedule and contributed revenue for the full quar
MARKET WIREYahoo • 5d ago
NRC Health Announces Third Quarter 2026 ResultsLINCOLN, Neb., October 27, 2026--NRC Health (NASDAQ: NRC), a leader in healthcare experience improvement solutions, today announced results for the third quarter 2026.
MARKET WIREBenzinga • 5d ago
National Research Q3 2026 Earnings Call TranscriptNational Research (NASDAQ:NRC) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga
CATALYSTBenzinga • 5d ago
National Research Q3 Adj. EPS $0.21, Inline, Sales $38.399M Beat $35.800M EstimateNational Research (NASDAQ:NRC) reported quarterly earnings of $0.21 per share which met the analyst consensus estimate. This is a 8.7 percent decrease over earnings of $0.23 per share from the same period last year.
MARKET WIREYahoo • 6d ago
NRC Health Launches nQuire Pro, Extending the Reach of Patient-Experience TeamsLINCOLN, Neb., October 26, 2026--NRC Health, a recognized leader in healthcare experience management, today announced the launch of nQuire Pro, a conversational analytics tool designed to help healthcare organizations ex
RISK WATCHBenzinga • 13d ago
NRC Health Appoints CEO Trent Green As Interim Principal Financial OfficerOn October 14, 2026, the board of directors of NRC Health, a Delaware corporation (the "Company"), designated Trent Green, the Company’s Chief Executive Officer, to serve as the Company’s interim principal
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (NRC Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NRC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +42.71%▲ ASCENDING CHANNEL
2026-10-30O $23.64H $24.01L $23.47C $23.49VOL 86.2K
RES: $28.08SUP: $19.92SMA50: $21.22SMA200: $19.17
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NRC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
33.4%/yr Implied 5Y Growth
vs. -4.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on NRC today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NRC. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NRC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NRC)
Health Care Rank #137 of 1016
⚔️ OABI vs NRC Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NRC vs. OABI, MXCT, ABSI, ONMD)
Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, NRC Health (NRC) ranks #137 by composite RQD confidence (65/100, grade C) and #440 by equity capitalization ($519.6M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. NRC currently leads its immediate peer cohort in composite quantitative strength at 65/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NRC
ACTIVE
NRC Health | C | 65/100 | 44.8x | — | 21.0% | +0.09% | $519.6M | Benchmark Subject |
| OABI OmniAb Inc. | D- | 38/100 | — | — | -22.6% | -0.95% | $760.4M | /oabi-vs-nrc → |
| MXCT MaxCyte Inc. | E | 30/100 | — | 96.0% | -27.1% | +1.17% | $178.5M | /mxct-vs-nrc → |
| ABSI Absci Corporation | D | 45/100 | — | — | -35.0% | +1.85% | $2.08B | /absi-vs-nrc → |
| ONMD OneMedNet Corp (Class A) | E | 29/100 | — | -30.0% | -35.0% | -2.02% | $26.3M | /onmd-vs-nrc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000070487In its most recent audited fiscal period (FY2025, filed 2025-12-31), NRC Health (NRC) reported GAAP revenue of $137.4M (-4.0% vs. FY2024 revenue of $143.1M , and -7.5% cumulative change since FY2023) , GAAP net income of $11.6M, operating cash flow of $26.4M, and free cash flow of $15.7M (-17.9% YoY). On the balance sheet, NRC closed FY2025 with $134.9M in total assets against $75.0M in total debt (Altman Z-Score: 3.82, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $137.4M | $11.6M | $26.4M | $15.7M | $134.9M | $75.0M |
| FY2024 (FY) | 2024-12-31 | $143.1M | $24.8M | $34.6M | $19.2M | $132.5M | $57.9M |
| FY2023 (FY) | 2023-12-31 | $148.6M | $31.0M | $38.1M | $38.1M | — | — |
3. NRC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NRC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, NRC Health (NASDAQ: NRC) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $23.49 (+0.09% 1D, market cap $519.6M). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, NRC ranks #137 in composite RQD confidence.
How does NRC compare to OABI and MXCT in the Health Care sector?
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), NRC carries a Roarable C (65/100 RQD), trailing P/E of 44.8x, gross margin of —, and ROIC of 21.0%. By comparison, OABI (OmniAb Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -22.6%, cap $760.4M) and MXCT (MaxCyte Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -27.1%, cap $178.5M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NRC?
Per NRC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000070487), NRC Health generated $137.4M in revenue (-4.0% YoY), $11.6M in net income, and $15.7M in free cash flow against $134.9M in total assets and $75.0M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 45x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NRC trading relative to its 50-day, 200-day, and 52-week technical levels?
NRC last traded at $23.49 (+0.09% on volume of 124,957 shares), positioning the stock +10.70% above its 50-day simple moving average ($21.22) and +22.54% above its 200-day simple moving average ($19.17). Across its 52-week range of $11.74 to $24.40, NRC sits at the 92.8% percentile with a 14-day RSI of 66.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.0% ($21.38 to $25.60).
NRC Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is NRC stock moving today?
Why NRC Stock advanced +0.09% Today — RQD Quant Desk Flash. Solid steady margins (21% return on capital), mixed timing at 45x P/E—hold if owned, no rush to chase.